| name | Risedronate |
| classification | Bisphosphonate |
| pharmacokinetics | | absorption | Risedronate is poorly absorbed from the gastrointestinal tract, typically around 1-2% of an oral dose is bioavailable. Absorption is affected by food, particularly calcium-rich foods, reducing absorption further. | | distribution | Risedronate is distributed throughout the body and primarily accumulated in bone. | | metabolism | Risedronate is primarily excreted unchanged in the urine. | | elimination | The elimination half-life is variable and depends on factors such as renal function, but it's generally measured in days. |
|
| suggested dosage | | adult male 25 years 70kg | The recommended dosage for risedronate to prevent osteoporosis or treat osteoporosis in men aged 25 is typically 5 mg once weekly or 35 mg once a month for patients with normal kidney function. This may vary based on specific clinical needs and should be determined by a physician. Important Note: Always follow the prescribed dosage and instructions from your physician. | | other details | The dosage needs to be individualized based on patient's needs, including severity of the condition, age, renal function, and concomitant medications. Never adjust dosages without direct medical supervision. |
|
| indications | | 1 | Prevention and treatment of osteoporosis in men (including those at high risk) | | 2 | Treatment of Paget's disease of the bone | | 3 | Treatment of glucocorticoid-induced osteoporosis |
|
| safety in pregnancy | Risedronate should not be used during pregnancy unless the potential benefits outweigh the potential risks to the fetus. There is insufficient evidence to support safety, and there is theoretical concern about potential adverse effects on the developing skeleton. |
| safety in breastfeeding | It's unknown whether risedronate is excreted in human milk. Therefore, use during breastfeeding is not recommended. |
| side effects | | 1 | Gastrointestinal issues (e.g., upset stomach, heartburn, abdominal pain, nausea, and rarely esophageal ulcers) | | 2 | Musculoskeletal pain (e.g., muscle or joint pain) | | 3 | Headache | | 4 | Fatigue | | 5 | Rarely, serious complications like esophageal erosions and/or ulcers (more likely with higher doses and/or non-adherence to instructions) |
|
| alternatives | |
| contraindications | | 1 | Hypersensitivity to risedronate or other bisphosphonates | | 2 | Esophageal abnormalities, such as stricture or achalasia | | 3 | Inability to remain upright for at least 30 minutes after taking the medication | | 4 | Severe renal impairment | | 5 | Active gastrointestinal ulcer or other conditions that could be exacerbated by the drug |
|
| interactions | | 1 | Other medications, particularly those affecting calcium absorption, can alter the effectiveness of risedronate. This must be carefully evaluated by the prescribing physician. | | 2 | Concurrent use of antacids can reduce absorption. |
|
| warnings and precautions | | 1 | Ensure adequate intake of calcium and vitamin D while using risedronate. The medication shouldn't be taken with or directly after other foods or drinks, including calcium-containing foods, for optimal absorption. | | 2 | Long-term use of high doses of bisphosphonates has been linked to atypical femur fractures (rare). Report any unusual hip, thigh or groin pain. | | 3 | Caution is advised in patients with pre-existing esophageal problems, active or recurrent upper GI disorders, or if there is difficulty swallowing. |
|
| additional information | Always consult with a healthcare professional for personalized advice. This information is for general knowledge only and does not constitute medical advice. It is crucial to discuss any concerns or potential risks with your doctor before taking risedronate or any other medication. The information provided should not be considered as a substitute for consultation with a qualified medical practitioner. |
